8 completed. 8 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 8 | Completed 8 |
Follow Meningococcal Disease: new trials by email Literature Review of Meningococcal Disease trials Research Report on Meningococcal Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Babies Born Early Antibody Response to Men B Vaccination: BEAR Men B 4CMenB Vaccine - Prematurity, Vaccination | Phase 4 | Completed | St George's, University of London | 136 | 2017-08-01 | 2020-12-01 |
| South Australian Meningococcal B Vaccine Herd Immunity Study Licensed 4CMenB vaccine - Meningococcal Disease | Phase 4 | Completed | University of Adelaide | 34489 | 2017-04-01 | 2019-07-02 |
| Hepatitis B Vaccination in Infants Menjugate, Menitorix, NeisVac-C - Meningococcal Disease, Pneumococcal Disease | Phase 4 | Completed | Public Health England | 300 | 2013-07-01 | 2020-10-01 |
| Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine - Meningococcal Disease | Phase 4 | Completed | Novartis Vaccines | 465 | 2013-05-01 | 2014-08-15 |
| Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects From 2 Months to 55 Years of Age in the Republic of South Korea MenACWY-CRM (Menveo) - Meningococcal Disease | Phase 4 | Completed | GlaxoSmithKline | 3948 | 2013-03-15 | 2018-09-21 |
| Understanding the Immune Response to Two Different Meningitis Vaccines MenACWY-CRM conjugate vaccine (Menveo, Novartis), MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) and MenACWY-CRM conjugate vaccine (Menveo, Novartis), 1/5th dose MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) and MenACWY-CRM conjugate vaccine (Menveo, Novartis) - Meningitis, Meningococcal Disease | Phase 4 | Completed | University of Oxford | 20 | 2012-12-01 | 2026-05-04 |
| Study of Sanofi Pasteur and Lanzhou Institute's Meningococcal (Group A and C) Polysaccharide Vaccine in Children Meningococcal (Groups A and C) Polysaccharide Vaccine - Meningococcal Disease, Meningitis | Phase 4 | Completed | Sanofi Pasteur, a Sanofi Company | 666 | 2011-08-01 | 2014-05-08 |
| Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate - Meningitis, Meningococcal Disease | Phase 4 | Completed | Sanofi Pasteur, a Sanofi Company | 538 | 2010-12-01 | 2014-11-14 |
Meningococcal Infections (8) · Meningitis (4) · Diphtheria (1) · Hepatitis B (1) · Pneumococcal Infections (1) · Premature Birth (1) · Tetanus (1) · Toxemia (1) · Whooping Cough (1)
Bacterial Infections (8) · Bacterial Infections and Mycoses (8) · Gram-Negative Bacterial Infections (8) · Infections (8) · Neisseriaceae Infections (8) · Nervous System Diseases (4) · Neuroinflammatory Diseases (4) · Actinomycetales Infections (1) · Blood-Borne Infections (1) · Bordetella Infections (1) · Clostridium Infections (1) · Communicable Diseases (1) · Corynebacterium Infections (1) · DNA Virus Infections (1) · Digestive System Diseases (1)
Meningococcal Vaccines (3) · 4CMenB vaccine (2) · MenC-CRM vaccine (1) · Polysaccharides (1) · halofantrine (1) · lactitol (1)
Sanofi Pasteur, a Sanofi Company (2) · GlaxoSmithKline (1) · Novartis Vaccines (1) · Public Health England (1) · St George's, University of London (1) · University of Adelaide (1) · University of Oxford (1)
United Kingdom (3) · Australia (1) · China (1) · Philippines (1) · South Korea (1) · Ukraine (1) · United States (1)
Andrew J Pollard, BA, MBBS, FRCPCH, PhD (1) · Elizabeth Coates, PhD (1) · Helen Marshall (1) · Paul Heath, MBBS (1)
PMID 31634044, PMID 31971677, PMID 32447370, PMID 32712083, PMID 33587122, PMID 38234190, PMID 38977298, PMID 40652683
2017 (1)